Cite

    Thomas Jax et al.. “A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.” Cardiovascular diabetology, vol. 16, no. 1, 2017, pp. 1–16. http://access.bl.uk/ark:/81055/vdc_100081036881.0x0000b7